Hyloris Sets Out IPO Terms

Value-Added Medicines Specialist Eyes US 505(b)(2) Opportunities

 
• By David Wallace
Euro
Hyloris has set out financial terms for its IPO • Source: Shutterstock

More from Strategy

More from Business